Clinical Trials Logo

Filter by:
NCT ID: NCT06015269 Recruiting - Solid Tumor Clinical Trials

Exploratory Study on Baize DC Injection in Preventing Recurrence and Metastasis After Radical Tumor Surgery

Start date: August 2023
Phase: Phase 1
Study type: Interventional

This is an exploratory study on the safety, immune response, and preliminary effectiveness of single arm, fixed dose therapy

NCT ID: NCT06015230 Recruiting - Clinical trials for Lupus Erythematosus, Systemic

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE

Start date: March 8, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

A Study to Investigate the Tolerability, Safety,Pharmacokinetics and efficacy of GR1603 in subjects with Systemic Lupus Erythematosus ; GR1603 injection is a monoclonal antibody targeting IFNAR1, which can block IFNAR binding to type I interferons such as IFNα and be used to treat systemic lupus erythematosus.

NCT ID: NCT06015178 Recruiting - Clinical trials for Medical Artificial Intelligence

Enhancing Medical Researchers' Self-learning With an Intelligent Language Model

Start date: August 30, 2023
Phase: N/A
Study type: Interventional

Solving medical scientific problems is a crucial driving force behind the advancement of medical disciplines. As the complexity of scientific questions increases, an increasing number of problems require interdisciplinary collaboration to be resolved. However, most medical researchers lack interdisciplinary background knowledge and require substantial time to systematically learn relevant knowledge and skills. Furthermore, the continuous emergence of new knowledge and skills emphasizes the importance of researchers' ability for autonomous learning in the medical field. Therefore, to promote the development of medical disciplines, there is an urgent need for an effective method to enhance researchers' self-directed learning abilities for conducting interdisciplinary research. The next-generation artificial intelligence language models, exemplified by ChatGPT, hold great potential in assisting researchers to access knowledge and information from various domains. Whether researchers can leverage such AI tools to enhance their self-directed learning abilities for conducting interdisciplinary research remains to be further explored. Additionally, concerns have been raised regarding the potential degradation of cognitive abilities through their use, although valid evidence is currently lacking. To investigate whether AI tools, represented by ChatGPT, can effectively assist medical researchers in conducting interdisciplinary research and whether their usage may negatively impact researchers' cognitive abilities, a randomized controlled trial is warranted. This trial aims to ascertain the potential benefits and risks associated with utilizing AI tools in the medical research domain.

NCT ID: NCT06015126 Recruiting - Breast Cancer Clinical Trials

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

Start date: October 5, 2022
Phase: N/A
Study type: Interventional

vinorelbine are one of the main chemotherapy drugs used in the treatment of advanced breast cancer. It is available in oral form, making it convenient to use and an ideal choice for rhythmic chemotherapy. In advanced breast cancer,metronomic oral vinorelbine chemotherapy has been the subject of several clinical studies, with proven effectiveness and good safety, showing great prospects for application. Considering the current lack of targeted, efficient, and convenient drugs for HER2-negative advanced breast cancer in later lines of treatment, and based on the preliminary efficacy of metronomic oral vinorelbine, anlotinib, and rhythmic chemotherapy in breast cancer, we plan to explore the efficacy and safety of combining metronomic oral vinorelbine chemotherapy with anlotinib in the treatment of HER2-negative advanced breast cancer, providing new data for the treatment of HER2-negative advanced breast cancer.

NCT ID: NCT06015061 Recruiting - Ultrasonography Clinical Trials

Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients

Start date: March 1, 2023
Phase:
Study type: Observational

Anlotinib is a multi-target receptor tyrosine kinase inhibitor (TKI) targeting tumor angiogenesis and growth. The purpose of this study is to evaluate the efficiency of contrast enhanced ultrasound in assessing effectiveness of anlotinib in patients with locally advanced, metastatic, or unresectable pheochromocytoma or paraganglioma(PPGL).

NCT ID: NCT06015048 Recruiting - Clinical trials for HER2-expressing Advanced Solid Tumors

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Start date: August 11, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A1811 combined with other antitumor therapies in advanced solid tumors. To explore the reasonable dosage of SHR-A1811 combined with other antitumor therapies for advanced solid tumors.

NCT ID: NCT06014996 Recruiting - Clinical trials for Paroxysmal Atrial Fibrillation

Comparison of PFA vs. RFA in Patients With Symptomatic Paroxysmal Atrial Fibrillation.

Start date: September 4, 2023
Phase: N/A
Study type: Interventional

This study is a mulitcentre, randomized, parallel-group evaluation of pulse field ablation(PFA) and radiofrequency ablation(RFA) in patients being treated for symptomatic paroxysmal AF. Pulmonary-vein isolation (PVI) is the primary intention of catheter ablation in both groups.

NCT ID: NCT06014775 Recruiting - Treatment Clinical Trials

Anti-CD38 Antibody Treating Evans Syndrome

2023-D-ES
Start date: December 2023
Phase: Phase 2
Study type: Interventional

A single-center, open-label, off-label use investigator-initiated clinical study with safety run-in to explore the clinical activity and safety of Anti-CD38 Antibody in adult ES patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including immunosuppressive agents, Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.

NCT ID: NCT06014723 Recruiting - Ischemic Stroke Clinical Trials

Balloon angiopLasty for Intracranial Atherosclerotic Minor Stroke/TIA

Start date: August 23, 2023
Phase:
Study type: Observational

The objective of this study was to evaluate the safety and efficacy of early submaximal balloon angioplasty combined with medical therapy vs medical therapy alone for minor stroke/transient ischemic attack with intracranial atherosclerosis etiology.

NCT ID: NCT06014528 Recruiting - Clinical trials for Ovarian Cancer Recurrent

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Start date: September 6, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, double-blind, phase II clinical study to evaluate the efficacy and safety of IN10018 in combination with PLD vs. placebo in combination with PLD in subjects with platinum-resistant recurrent ovarian cancer (including fallopian tube and primary peritoneal cancers).